HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.

AbstractBACKGROUND:
MYCN amplification (MNA) in neuroblastoma is a strong indicator of poor prognosis. However, some MYCN nonamplified (non-MNA) cases show poor outcomes, and examining the status of the gene requires an operation, which may have surgical complications. Therefore, a new marker is needed to identify cases of non-MNA neuroblastomas with poor prognoses using less risky procedures. Aberrant hypermethylation of the DCR2 promoter has recently been associated with rapidly progressing neuroblastoma. We aimed to develop a noninvasive DCR2 methylation assay for patients with neuroblastoma using serum DNA, which predominantly originates from tumor-released DNA.
METHODS:
Using DNA-based real-time PCR, we simultaneously quantified a methylated-DCR2 specific sequence (M) and a reference sequence (R) located in the promoter region in serum DNA, and evaluated DCR2 methylation status as M/R ratios in 86 patients with neuroblastoma.
RESULTS:
Serum DCR2 M/R ratios were strongly correlated with those in the tumor (r=0.67; P=0.002). DCR2 methylation was associated with stage both in the whole neuroblastoma group and in the non-MNA group (P<0.001), and DCR2-methylated patients showed significantly poorer 5-year event-free survival in the whole neuroblastoma group (43% versus 84%; P<0.001), especially in the non-MNA group (12% versus 96%;P<0.001). Among five DCR2-methylated patients whose clinical courses were followed, serum M/R ratios were close to 0 in the patients in remission, whereas the ratios increased in patients who relapsed.
CONCLUSIONS:
Detection of methylated-DCR2 in serum DNA has promise as a noninvasive assay for predicting prognosis and therapeutic efficacy in neuroblastoma, especially in non-MNA cases. Furthermore, it might be a sensitive marker of tumor recurrence in DCR2-methylated cases.
AuthorsShigeki Yagyu, Takahiro Gotoh, Tomoko Iehara, Mitsuru Miyachi, Yoshiki Katsumi, Satoko Tsubai-Shimizu, Ken Kikuchi, Shinichi Tamura, Kunihiko Tsuchiya, Toshihiko Imamura, Akiko Misawa-Furihata, Tohru Sugimoto, Tadashi Sawada, Hajime Hosoi
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 14 Issue 21 Pg. 7011-9 (Nov 1 2008) ISSN: 1078-0432 [Print] United States
PMID18980997 (Publication Type: Evaluation Studies, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • MYCN protein, human
  • Nuclear Proteins
  • Oncogene Proteins
  • TNFRSF10D protein, human
  • Tumor Necrosis Factor Decoy Receptors
Topics
  • DNA Methylation
  • Female
  • Gene Amplification
  • Humans
  • Infant
  • Male
  • Neuroblastoma (blood, diagnosis, genetics, therapy)
  • Nuclear Proteins (genetics)
  • Oncogene Proteins (genetics)
  • Prognosis
  • Treatment Outcome
  • Tumor Necrosis Factor Decoy Receptors (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: